OTCMKTS:ALPMY Astellas Pharma (ALPMY) Stock Price, News & Analysis $11.66 -0.02 (-0.17%) (As of 11/1/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort Interest About Astellas Pharma Stock (OTCMKTS:ALPMY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Astellas Pharma alerts:Sign Up Key Stats Today's Range$11.39▼$12.1150-Day Range$11.28▼$12.6452-Week Range$9.15▼$13.14Volume51,601 shsAverage Volume234,402 shsMarket Capitalization$21.10 billionP/E Ratio55.53Dividend Yield2.57%Price TargetN/AConsensus RatingN/A Company OverviewAstellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.Read More… 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Receive ALPMY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Astellas Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address ALPMY Stock News HeadlinesAstellas Pharma H1 Profit Rises; Lifts FY24 OutlookOctober 30 at 7:28 AM | markets.businessinsider.comAstellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest UpdateOctober 29, 2024 | americanbankingnews.comCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!November 2, 2024 | Crypto 101 Media (Ad)Astellas Pharma Withdraws EU Application for Key DrugOctober 28, 2024 | markets.businessinsider.comBernstein Releases a Buy Rating on Astellas Pharma (ALPMF)October 23, 2024 | markets.businessinsider.comAstellas Pharma’s VYLOY Gains FDA Approval for Cancer TreatmentOctober 21, 2024 | markets.businessinsider.comAstellas Pharma's Cancer Drug Vyloy Gets FDA ApprovalOctober 19, 2024 | marketwatch.comAstellas Pharma's VYLOY Receives FDA Approval For Treatment Of Advanced Gastric And GEJ CancerOctober 19, 2024 | markets.businessinsider.comSee More Headlines ALPMY Stock Analysis - Frequently Asked Questions How have ALPMY shares performed this year? Astellas Pharma's stock was trading at $11.90 at the beginning of the year. Since then, ALPMY shares have decreased by 2.0% and is now trading at $11.66. View the best growth stocks for 2024 here. How were Astellas Pharma's earnings last quarter? Astellas Pharma Inc. (OTCMKTS:ALPMY) issued its earnings results on Wednesday, October, 30th. The company reported $0.13 earnings per share for the quarter. The company had revenue of $3.11 billion for the quarter. Astellas Pharma had a net margin of 3.26% and a trailing twelve-month return on equity of 10.33%. When did Astellas Pharma's stock split? Shares of Astellas Pharma split on the morning of Wednesday, April 2nd 2014. The 5-4 split was announced on Friday, March 14th 2014. The newly created shares were issued to shareholders after the market closes on Tuesday, April 1st 2014. An investor that had 100 shares of stock prior to the split would have 125 shares after the split. Does Astellas Pharma have any subsidiaries? The following companies are subsidiaries of Astellas Pharma: Iota Biosciences, Nanna Therapeutics, Xyphos, Audentes Therapeutics, Potenza Therapeutics, Quethera, Universal Cells Inc., and others. How do I buy shares of Astellas Pharma? Shares of ALPMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings10/30/2024Today11/02/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:ALPMY CUSIPN/A CIK1446390 Webwww.astellas.com Phone(133) 244-3000FaxN/AEmployees14,754Year Founded1923Profitability EPS (Most Recent Fiscal Year)$0.21 Trailing P/E Ratio55.53 Forward P/E Ratio19.76 P/E GrowthN/ANet Income$113 million Net Margins3.26% Pretax Margin1.55% Return on Equity10.33% Return on Assets4.62% Debt Debt-to-Equity Ratio0.26 Current Ratio0.90 Quick Ratio0.72 Sales & Book Value Annual Sales$11.11 billion Price / Sales1.90 Cash Flow$1.10 per share Price / Cash Flow10.64 Book Value$5.84 per share Price / Book2.00Miscellaneous Outstanding Shares1,809,660,000Free FloatN/AMarket Cap$21.10 billion OptionableNot Optionable Beta0.37 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report This page (OTCMKTS:ALPMY) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredThe Final FrontierAnd a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astellas Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Astellas Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.